NovoCure Limited

NVCR Healthcare Medical Devices

NovoCure Limited’s revenue for fiscal 2025 (year ended December 2025) was $655.4 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 63.9%, free cash flow grew 105.7% and total debt rose 100.7%, each against the same quarter a year earlier.

14.07 0.34 −2.36%
Market cap
$1.7B
P/E
0.0×
Fwd P/E
−10.8×
Dividend yield
—
F-score
4/9
Altman Z
0.43
Beneish M
−2.12
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Net Income
(136.23) (168.63) (207.04) (92.53) (58.35) 19.81 (7.23) (63.56) (61.66) (131.84)
Depreciation & Amortization
(8.61) (14.41) (12.11) 9.09 13.35 12.41 6.28 10.03 7.93 5.81
Non Cash Items (Other)
115.88 160.32 116.17 102.44 98.69 75.45 51.90 40.25 27.36 28.59
Accounts Receivable Change
(38.94) (26.36) 29.41 2.55 5.27 (30.35) (36.50) (10.32) (21.25) (6.10)
Change in inventories
(5.67) 2.57 (8.92) (4.34) 2.48 (2.93) (1.16) (0.53) 3.52 (11.95)
Accounts Payable Change
— — — — 27.78 25.47 16.88 13.71 (1.15) 1.60
Change in payables and accrued liability
18.96 19.11 14.87 14.26 27.78 25.47 16.88 9.50 14.46 6.65
Change in other assets and liabilities
5.57 1.04 (5.71) (0.67) (6.46) (0.70) (3.56) 8.55 (2.34) 0.36
Other operating activities
— — — — — — — — — (0.70)
Operating Cash Flow
(49.03) (26.37) (73.34) 30.79 82.76 99.15 26.62 (1.86) (33.13) (107.59)
Capital expenditures
(26.65) (42.85) (27.09) (21.36) (24.17) (14.97) (10.48) (6.71) (7.37) (17.66)
Short Term Investments Change (Net)
463.92 (97.39) 211.24 (118.60) (120.66) (457.88) (41.18) 1.22 15.99 30.66
Other investing activities
— — — — — — — — — (0.18)
Investing cash flow
437.28 (140.24) 184.15 (139.96) (144.83) (472.85) (51.67) (5.49) 8.63 12.82
Repayment/Issuance of Debt (Net)
(460.97) 84.01 (0.01) (0.03) (0.03) 408.41 (0.03) 49.07 (0.06) 72.82
Equity Repurchase (Common, Net)
9.77 6.31 15.80 15.52 25.73 31.80 61.71 20.30 5.23 1.61
Other financial activities
(0.15) — — 103.12 101.88 78.71 49.72 41.28 27.61 0.70
Financing cash flow
(451.34) 90.32 15.79 15.49 25.70 440.21 61.68 69.37 5.17 75.12
Exchange Rate Adjustment
0.39 (0.17) 0.13 (0.10) (0.19) 0.25 0.03 0.03 0.01 0.01
Change in Cash
(62.70) (76.47) 126.73 (93.77) (36.56) 66.76 36.66 62.04 (19.33) (19.64)
Beginning Cash
166.09 242.56 115.83 209.61 246.17 179.42 142.76 80.72 100.05 119.42
Ending Cash
103.39 166.09 242.56 115.83 209.61 246.17 179.42 142.76 80.72 99.78
Stock Based Compensation
104.83 160.04 115.61 106.96 94.90 75.72 52.42 39.85 27.12 22.14
Dividends Paid (Common)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash/Marketcap
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
(20.07) (3.65) 29.66 11.80 29.07 (8.52) (24.33) 11.41 (6.76) (9.44)
Investments Change (Net)
463.92 (97.39) 211.24 (118.60) (120.66) (457.88) (41.18) 1.22 15.99 30.66
Issuance/Purchase of Shares
9.77 6.31 15.80 15.52 25.73 31.80 61.71 20.30 5.23 1.61
Other line items
Revenue per Employee
0.41 0.41 0.35 0.41 0.46 0.48 0.45 0.41 0.36 0.18

Fold the line items

In millions of $ except per-share values · columns are period end dates